Skip to main content
Fig. 4 | Genome Biology

Fig. 4

From: Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients

Fig. 4

Patients with pre-existing cardiomyopathy show an increased mortality rate. A Kaplan-Meier curve of COVID19 patients with pre-existing cardiomyopathy (N = 43), patients with other pre-existing cardiovascular diseases (N = 624), and patients without cardiovascular diseases (N = 3269). P values are from Cox proportional-hazards models, controlling for differences in the demographics and non-cardiovascular conditions between the groups. B Kaplan-Meier curve of COVID19 patients with pre-existing cardiomyopathy (N = 43) and a cohort of propensity score-matched patients with other pre-existing cardiovascular diseases (N = 344). P values are from a log-rank test. C Kaplan-Meier curve of COVID-19-negative patients with pre-existing cardiomyopathy (N = 2250) and a cohort of propensity score-matched patients with other pre-existing cardiovascular diseases (N = 18,000). P values are from a log-rank test

Back to article page